The White House
released a “Bioeconomy Blueprint” last
week outlining an approach to harness innovations and address national
challenges in health, food, energy and the environment. The Blueprint is
designed to guide work among federal agencies and with the private-sector to
enhance economic growth, job creation, and innovation.
concert with the Blueprint release, a number of federal agency commitments supportive of the Blueprint’s goals were made
public. Among them are initiatives to encourage federal procurement of an
expanded range of bio-based products; take better advantage of large
pharmaceutical data sets to speed drug development; apply the latest genomics
discoveries to quickly identify emerging microbial threats; and accelerate
research on non-embryonic stem cells as possible treatments for blood-related
and neurological diseases.
Specifically, one of the commitments states
that the NIH Center for Regenerative Medicine and its partners are exploring
the development of induced pluripotent stem (iPS) cell therapies to treat blood-related
diseases such as leukemia and that the researchers will investigate whether iPS
cells can be used to develop blood products that could help meet the demand for
blood transfusions during medical emergencies and surgeries. Please see
page 18 of the Bioeconomy Blueprint and page 2 of the
commitments document for more information.
Blueprint and the federal agency commitments that will help implement it are
consistent with the ASH
Agenda for Hematology Research, a strategic plan that the Society
recently released, which identifies the most promising areas of research that
require ongoing support.
back to top